| pubmed-article:8178407 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C0085957 | lld:lifeskim |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C1336527 | lld:lifeskim |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C1415904 | lld:lifeskim |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C0814337 | lld:lifeskim |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8178407 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:8178407 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8178407 | pubmed:dateCreated | 1994-6-9 | lld:pubmed |
| pubmed-article:8178407 | pubmed:abstractText | A total of 78 patients with superficial bladder carcinoma were prospectively randomized to two groups following complete transurethral resection (TUR). Each received 12 intravesical instillations of 10(7) units interferon A or 120 mg BCG Connaught for 1 year starting 6 weeks post-TUR. After a mean observation period of 24 (13-31) months in the BCG and 25 (6-32) months in the IFN group 5/32 (15.6%) recurrences in the BCG versus 21/35 (60%) in the IFN group were observed (P = 0.0003). In the IFN group 18.4% of the patients had dysuria and 2.6% fever; in the BCG group 35% had fever, 60% cystitis, 1 patient granulomatous epididimoorchitis and 1 patient pneumonitis with granulomatous prostatitis. With our instillation regimen interferon A had few side effects but also no prophylactic effect, whereas BCG had tolerable-seldom severe--side effects and was very effective in preventing recurrences. Perhaps IFN should be given earlier after TUR and in a higher dosage. | lld:pubmed |
| pubmed-article:8178407 | pubmed:language | ger | lld:pubmed |
| pubmed-article:8178407 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8178407 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8178407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8178407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8178407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8178407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8178407 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8178407 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8178407 | pubmed:issn | 0340-2592 | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:BeerMM | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:KleinEE | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:LinkMM | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:FabriciusP... | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:MendozaEE | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:IkingerUU | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:KälbleTT | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:ReichertH EHE | lld:pubmed |
| pubmed-article:8178407 | pubmed:author | pubmed-author:FrangenheimTT | lld:pubmed |
| pubmed-article:8178407 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8178407 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:8178407 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8178407 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8178407 | pubmed:pagination | 133-7 | lld:pubmed |
| pubmed-article:8178407 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:meshHeading | pubmed-meshheading:8178407-... | lld:pubmed |
| pubmed-article:8178407 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8178407 | pubmed:articleTitle | [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study]. | lld:pubmed |
| pubmed-article:8178407 | pubmed:affiliation | Urologische Abteilung, Chirurgischen Universitäts-Klinik Heidelberg. | lld:pubmed |
| pubmed-article:8178407 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8178407 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8178407 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8178407 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:8178407 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8178407 | lld:pubmed |
